Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment

  • M. Benucci | maurizio.benucci@uslcentro.toscana.it Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
  • A. Damiani Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
  • A. Arena Nuclear Medicine Unit, New Hospital, Prato, Italy.
  • M. Infantino Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
  • M. Manfredi Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, Firenze, Italy.
  • F. Li Gobbi Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze, Italy.

Abstract

We observed a 69-year old man suffering from HLA B27 ankylosing spondylitis with persistent night back pain. 18F-FDG-PET/CT showed an increased metabolism at the level of the spinal space of L2-L3, L3-L4 with increased uptake compatible with spondylodiscitis. He started therapy with etanercept 50 mg/week. After six months of treatment repeated testing showed no uptake of the discs and vertebral bodies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Author Biography

M. Benucci, Rheumatology Unit, S. Giovanni di Dio Hospital, Firenze
Internal Medicine
Published
2016-12-16
Info
Issue
Section
Radiological vignette
Keywords:
Spondylodiscitis, etanercept, ankylosing spondylitis.
Statistics
  • Abstract views: 2593

  • PDF: 516
How to Cite
Benucci, M., Damiani, A., Arena, A., Infantino, M., Manfredi, M., & Li Gobbi, F. (2016). Aseptic HLA B27-positive spondylodiscitis: decreased 18F-FDG uptake after etanercept treatment. Reumatismo, 68(3), 163-165. https://doi.org/10.4081/reumatismo.2016.911